Nalaganje...
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
BACKGROUND: Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challenging to in...
Shranjeno v:
| izdano v: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5815238/ https://ncbi.nlm.nih.gov/pubmed/29448920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4108-0 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|